US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

8.65

-0.2900-3.24%

Volume:968.77K

Turnover:8.42M

Market Cap:270.66M

PE:-3.04

High:9.25

Open:8.90

Low:8.40

Close:8.94

52wk High:50.40

52wk Low:8.40

Shares:31.29M

Float Shares:15.69M

Volume Ratio:0.50

T/O Rate:6.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8500

EPS(LYR):-2.8503

ROE:-33.63%

ROA:-21.86%

PB:0.95

PE(LYR):-3.03

Loading ...

Overview Company News Filings

Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Denali Therapeutics Is Maintained at Overweight by Morgan Stanley

Rapid Dose Therapeutics Details 2026 Strategy and Global Expansion Drive

JW Therapeutics Boosts 2025 Revenue on CAR-T Sales and Licensing but Books Major Pipeline Impairments

Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.

EXACT Therapeutics Registers Share Capital Increase After Warrant Exercise

Press Release: Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

Denali Therapeutics price target raised to $41 from $34 at Stifel

Morgan Stanley Lifts Price Target on Denali Therapeutics to $42 From $40, Keeps Overweight Rating

MT Newswires Live

Lenz Therapeutics price target lowered to $26 from $52 at Citi

Modalis Therapeutics Issues 18th Series Stock Options to Align Incentives and Retain Talent

Outlook Therapeutics Completes Dilutive Equity Offering With Warrants

Press Release: Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Press Release: Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Silexion Therapeutics Announces Immediate Board Membership Change

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LENZ/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":8.65,"timestamp":1774640015346,"preClose":8.94,"halted":0,"volume":968766,"delay":0,"changeRate":-0.032438478747203486,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"Trading","change":-0.29,"latestTime":"03-27 15:33:42 EDT","open":8.9,"high":9.25,"low":8.395,"amount":8416086.81138,"amplitude":0.095638,"askPrice":8.66,"askSize":106,"bidPrice":8.64,"bidSize":171,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774641600000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":8.94,"preHourTrading":{"tag":"盘前","latestPrice":8.95,"preClose":8.94,"latestTime":"09:25 EDT","volume":2891,"amount":25925.149467,"timestamp":1774617913255,"change":0.01,"changeRate":0.001119,"amplitude":0.016779},"postHourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"19:59 EDT","volume":36279,"amount":324346.69,"timestamp":1774569585377,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.49949,"impliedVol":1.2637,"impliedVolPercentile":0.9753},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-21.86%","roe":"-33.63%","lyrEps":-2.850329,"volumeRatio":0.49949,"shares":31289969,"dividePrice":0,"high":9.25,"amplitude":0.095638,"preClose":8.94,"low":8.395,"week52Low":8.395,"pbRate":"0.95","psRate":"14.18","week52High":50.4,"institutionHeld":0,"latestPrice":8.65,"committee":0.234657,"eps":-2.85,"divideRate":0,"volume":968766,"delay":0,"ttmEps":-2.85,"open":8.9,"prevYearClose":16,"prevWeekClose":10.48,"prevMonthClose":13.49,"prevQuarterClose":16,"fiveDayClose":10.48,"twentyDayClose":13.49,"sixtyDayClose":16.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-03-26","current":-3.136842,"percent":0.997925,"low":-26.69966,"twenty":-16.983941,"median":-11.233899,"eighty":-7.517786,"high":-3.447468,"avg":-12.486496,"sd":5.197013,"marketCap":284384353},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-26","current":-3.462739,"twenty":-16.983941,"median":-11.233899,"eighty":-7.517786,"marketCap":284384353}],"updateTime":1774614601100},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622961148","title":"Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2622961148","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622961148?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:06","pubTimestamp":1774555616,"startTime":"0","endTime":"0","summary":"Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $(0.40) by 232.5 percent. This is a 239.47 percent increase over losses of $(0.38) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51494928/spero-therapeutics-q4-eps-0-53-beats-0-40-estimate-sales-41-297m-up-from-15-044m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2622891613","title":"Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891613?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapita","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263414/0/en/Rani-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2622651891","title":"Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622651891","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622651891?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero’s l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263404/0/en/Spero-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Operating-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2622989831","title":"Denali Therapeutics Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989831","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989831?lang=en_us&edition=fundamental","pubTime":"2026-03-27 01:56","pubTimestamp":1774547760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DNLI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 13:56 ET (17:56 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2622886645","title":"Rapid Dose Therapeutics Details 2026 Strategy and Global Expansion Drive","url":"https://stock-news.laohu8.com/highlight/detail?id=2622886645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622886645?lang=en_us&edition=fundamental","pubTime":"2026-03-26 22:12","pubTimestamp":1774534347,"startTime":"0","endTime":"0","summary":"Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an update. Rapid Dose Therapeutics outlined a 2026 strategic update emphasizing its resil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapid-dose-therapeutics-details-2026-strategy-and-global-expansion-drive?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapid-dose-therapeutics-details-2026-strategy-and-global-expansion-drive?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2622599868","title":"JW Therapeutics Boosts 2025 Revenue on CAR-T Sales and Licensing but Books Major Pipeline Impairments","url":"https://stock-news.laohu8.com/highlight/detail?id=2622599868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622599868?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:52","pubTimestamp":1774529540,"startTime":"0","endTime":"0","summary":"The latest update is out from JW (Cayman) Therapeutics Co. Ltd. ( ($HK:2126) ). JW (Cayman) Therapeutics reported a 79.3% year-on-year rise in 2025...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jw-therapeutics-boosts-2025-revenue-on-car-t-sales-and-licensing-but-books-major-pipeline-impairments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jw-therapeutics-boosts-2025-revenue-on-car-t-sales-and-licensing-but-books-major-pipeline-impairments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAR","LENZ"],"gpt_icon":0},{"id":"2622857692","title":"Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622857692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622857692?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:18","pubTimestamp":1774527480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 08:18 ET (12:18 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2622854765","title":"EXACT Therapeutics Registers Share Capital Increase After Warrant Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854765","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854765?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:37","pubTimestamp":1774525042,"startTime":"0","endTime":"0","summary":"EXACT Therapeutics AS ( ($DE:56F) ) has issued an update. EXACT Therapeutics has completed the registration of new shares issued following the rece...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/exact-therapeutics-registers-share-capital-increase-after-warrant-exercise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/exact-therapeutics-registers-share-capital-increase-after-warrant-exercise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4202","BK4007","LENZ","AS","BK4139"],"gpt_icon":0},{"id":"2622085468","title":"Press Release: Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622085468","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622085468?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"\"Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry,\" said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. \"He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his breadth of connections throughout the global diagnostics industry will help the Company maximize the positive impact of CNSide on patients with central nervous system cancers and drive value for stockholders.\". Mr. Andrews added, \"CNSide represents an important leap forward in technology, utilizing cerebrospinal fluid to help physicians better identify and manage leptomeningeal metastases. I'm pleased to join Plus's board and to work closely with my fellow board members and management to optimize its strategy and path forward in its diagnostics business.\". CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that devel","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4135","LENZ","BK4022","BK4232","PSTV","BK4139","CNS","R"],"gpt_icon":0},{"id":"2622512538","title":"HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2622512538","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622512538?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"IR@hookipapharma.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262861/0/en/HOOKIPA-Pharma-Announces-Completion-of-Sale-of-Oncology-Assets-to-NeoTrail-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SITC","LENZ","BK4080","BK4231","BK4139","BK4007"],"gpt_icon":0},{"id":"2622859835","title":"Denali Therapeutics price target raised to $41 from $34 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2622859835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622859835?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:35","pubTimestamp":1774521347,"startTime":"0","endTime":"0","summary":"Stifel analyst Paul Matteis raised the firm’s price target on Denali Therapeutics (DNLI) to $41 from $34 and keeps a Buy rating on the shares follo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-price-target-raised-to-41-from-34-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-price-target-raised-to-41-from-34-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","LENZ"],"gpt_icon":0},{"id":"2622759856","title":"Morgan Stanley Lifts Price Target on Denali Therapeutics to $42 From $40, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2622759856","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622759856?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:33","pubTimestamp":1774521234,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (DNLI) has an average rating of buy and mean price target of $35.13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2622885985","title":"Lenz Therapeutics price target lowered to $26 from $52 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2622885985","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622885985?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:31","pubTimestamp":1774521064,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz lowered the firm’s price target on Lenz Therapeutics (LENZ) to $26 from $52 and keeps a Buy rating on the shares. Pu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lenz-therapeutics-price-target-lowered-to-26-from-52-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lenz-therapeutics-price-target-lowered-to-26-from-52-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2622832317","title":"Modalis Therapeutics Issues 18th Series Stock Options to Align Incentives and Retain Talent","url":"https://stock-news.laohu8.com/highlight/detail?id=2622832317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622832317?lang=en_us&edition=fundamental","pubTime":"2026-03-26 15:53","pubTimestamp":1774511637,"startTime":"0","endTime":"0","summary":"Modalis Therapeutics Corporation ( ($JP:4883) ) has shared an announcement. Modalis Therapeutics has approved the issuance of its 18th series of st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/modalis-therapeutics-issues-18th-series-stock-options-to-align-incentives-and-retain-talent?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/modalis-therapeutics-issues-18th-series-stock-options-to-align-incentives-and-retain-talent?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2622000058","title":"Outlook Therapeutics Completes Dilutive Equity Offering With Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000058","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000058?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:34","pubTimestamp":1774474477,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On March 23, 2026, Outlook Therapeutics, Inc. launched a best-efforts public offeri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-completes-dilutive-equity-offering-with-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-completes-dilutive-equity-offering-with-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","LENZ","BK4139","BK4007","BK4588","BK4539","BK4585","EQR"],"gpt_icon":0},{"id":"2622700086","title":"Press Release: Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622700086","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622700086?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:30","pubTimestamp":1774474200,"startTime":"0","endTime":"0","summary":"SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results for the fourth quarter and year ended December 31, 2025 and provides an update on recent corporate developments.\"While we have consistently made meaningful and measurable progress across our -endoxifen development strategy in oncology over the last 12 months, we continue to explore the best opportunities to leverage the technology where it may help to address serious health conditions and unmet medical needs. As we continue to keep a careful eye on opportunities in the breast cancer space, we are also diligently working to advance -endoxifen in certain rare disease indications, such as Duchenne Muscular Dystrophy  and McCune-Albright Syndrome ,\" stated Dr. Steven Quay, M.D., Ph.D., Atossa Therapeutics' President and Chief Executive Officer. \"To date, we ha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4079","LU2413665964.HKD","LU2413666004.HKD","BK4585","LU1543694498.USD","LU1165135440.EUR","LU1596574779.USD","LABU","BK4588","LU1620156130.USD","LENZ","MAS","Z","LU1620156213.USD","BK4539","LU1721427968.SGD","BK4548","LU0170899867.USD","BK4551","BK4086","BK4139","BK4007","SG9999001440.SGD"],"gpt_icon":0},{"id":"2622007889","title":"Press Release: Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007889","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007889?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:53","pubTimestamp":1774471980,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., March 25, 2026  -- Rani Therapeutics Holdings, Inc.  , a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Hiland as Head of Strategy. Mr. Hiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease.\"What attracted me to Rani is the strength of its platform and the breadth of opportunity it creates across multiple therapeutic areas,\" said Mr. Hiland. \"The ability to deliver biologics orally has the potential to reshape treatment paradigms, and I believe Rani i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","BK4022","RANI","LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2622007325","title":"Silexion Therapeutics Announces Immediate Board Membership Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007325","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007325?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:42","pubTimestamp":1774471325,"startTime":"0","endTime":"0","summary":"An update from Silexion Therapeutics ( ($SLXN) ) is now available. On March 25, 2026, Silexion Therapeutics Corp. announced that its Board of Direc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/silexion-therapeutics-announces-immediate-board-membership-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/silexion-therapeutics-announces-immediate-board-membership-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2622888167","title":"Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622888167","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622888167?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:20","pubTimestamp":1774470000,"startTime":"0","endTime":"0","summary":"- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March  25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262599/0/en/Serina-Therapeutics-Reports-Full-Year-2025-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IND","BK4139","TD","BK4566","BK4585","LENZ","BK4207","BK4007"],"gpt_icon":0},{"id":"2622004617","title":"Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004617","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004617?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469100,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 25, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Each common warrant has an exercise price of $0.25 per share, is exercisable immediately and expires five years from the date of issuance.The aggregate gross proceeds of the offering were $5.0 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to Outlook Therapeutics from the common warrants, if fully exercised on a cash basis, will be approximately $5.0 million. No assurance can be given that any of the common wa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4539","BK4585","BK4588","LENZ","03160","OTLK","BK4604","BK4139","BK4099","TM","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":2,"totalSize":262,"code":"91000000","status":"200"}]}}